- Home
- SBGI vs PHAT Comparison
SBGI vs PHAT Comparison
Compare SBGI & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBGI | PHAT |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | 7100 | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 894.0M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SBGI | PHAT |
|---|---|---|
| Price | $14.35 | $11.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $22.00 | $19.83 |
| AVG Volume (30 Days) | 405.0K | ★ 1.4M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 6.56% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $3,169,000,000.00 | $175,110,000.00 |
| Revenue This Year | $12.37 | $93.04 |
| Revenue Next Year | N/A | $58.91 |
| P/E Ratio | $50.18 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $11.89 | $3.69 |
| 52 Week High | $17.88 | $18.31 |
Technical Indicators
Market Signals| Indicator | SBGI | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 45.49 |
| Support Level | $13.34 | $10.38 |
| Resistance Level | $15.48 | $11.90 |
| Average True Range (ATR) | 0.60 | 0.97 |
| MACD | -0.14 | -0.06 |
| Stochastic Oscillator | 25.50 | 52.46 |
Price Performance
Historical ComparisonAbout SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.